Biopharma is no longer just a health issue. It is a geopolitical and economic priority.

In the global race for innovation, countries are investing in biotech as strategically as in AI and quantum technology to secure talent, capital and future value chains.

Our new EFPIA report examines how 10 leading countries have strengthened their biopharmaceutical ecosystems after COVID and what Europe must do to stay competitive.

With the US and China accelerating and Asia expanding its share of the global pipeline, the question is clear: Can Europe turn scientific excellence into global leadership?